Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled cross-over study.

@article{BerthJones1990FailureOP,
  title={Failure of papaverine to reduce pruritus in atopic dermatitis: a double-blind, placebo-controlled cross-over study.},
  author={John Berth-Jones and Robin A. C. Graham-Brown},
  journal={The British journal of dermatology},
  year={1990},
  volume={122 4},
  pages={553-7}
}
Papaverine has been reported, largely on the basis of clinical experience, to reduce the severity of pruritus associated with atopic dermatitis. A double-blind, placebo-controlled, cross-over study was performed to assess the degree of improvement. Fifty subjects with atopic dermatitis each received papaverine 100 mg q.d.s. orally for 4 weeks and another 4 weeks of matching placebo in randomized order. The parameters used to measure response were pruritus as assessed on visual analogue scales… CONTINUE READING